Shandong Weigao Group Medical Polymer (1066) Fundamentals 2026 — P/E 8.1x, Revenue Analysis | SniperIQ
Shandong Weigao Group Medical Polymer (1066) is a CN-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of HK
.27 on the HKSE. This SniperIQ fundamentals page covers Shandong Weigao Group Medical Polymer's valuation (P/E 8.1x, P/B 0.5x), profitability (net margin 12.0%), revenue (¥13.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shandong Weigao Group Medical Polymer's market cap?
Shandong Weigao Group Medical Polymer (1066) has a market capitalization of approximately HK
.27 on the HKSE. Market cap moves with the live share price.What is Shandong Weigao Group Medical Polymer's P/E ratio?
Shandong Weigao Group Medical Polymer's trailing twelve-month P/E ratio is 8.1x, with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shandong Weigao Group Medical Polymer?
Shandong Weigao Group Medical Polymer runs a net profit margin of 12.0%, a gross margin of 47.3%, and an operating margin of 12.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shandong Weigao Group Medical Polymer generate?
Shandong Weigao Group Medical Polymer reported revenue of ¥13.4B for fiscal year 2025, with net income of ¥1.6B and earnings per share (EPS) of 0.35. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shandong Weigao Group Medical Polymer pay a dividend?
Shandong Weigao Group Medical Polymer offers a trailing dividend yield of about 5.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shandong Weigao Group Medical Polymer financially healthy?
Shandong Weigao Group Medical Polymer carries a debt-to-equity ratio of 0.25x and a current ratio of 3.78x, with a market beta of 0.35. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shandong Weigao Group Medical Polymer a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shandong Weigao Group Medical Polymer (1066) the key facts are: market cap HK
Track Shandong Weigao Group Medical Polymer's full fundamentals live
Get Shandong Weigao Group Medical Polymer's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.